<--- Back to Details
First PageDocument Content
Medicine / Health / Clinical medicine / Clinical pharmacology / GABAA receptor positive allosteric modulators / Complement deficiency / Hereditary angioedema / Serpinopathies / Icatibant / Adverse effect / Clinical trial / Zolpidem
Date: 2016-07-27 08:20:03
Medicine
Health
Clinical medicine
Clinical pharmacology
GABAA receptor positive allosteric modulators
Complement deficiency
Hereditary angioedema
Serpinopathies
Icatibant
Adverse effect
Clinical trial
Zolpidem

Microsoft Word - FIRAZYR.Product Monographdoc

Add to Reading List

Source URL: www.shirecanada.com

Download Document from Source Website

File Size: 485,17 KB

Share Document on Facebook

Similar Documents

Medicine / Health / Complement deficiency / Clinical medicine / Angioedema / Adverse effect / Hereditary angioedema

[Product Monograph Template - Schedule D]

DocID: 1qWQL - View Document

Blood / Coagulation system / Anatomy / CSL Behring / Von Willebrand disease / Factor VIII / Coagulation / CSL Limited / Hereditary angioedema / Haemophilia / Factor IX / Factor VII

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

Neurochemistry / Medicine / Clinical medicine / Complement deficiency / RTT / Sodium channel blockers / Euphoriants / Calcium channel blockers / Hereditary angioedema / Syringe / Angioedema / Ketamine

Microsoft Word - CINRYZE.Product Monographdoc

DocID: 1qE2h - View Document

Medicine / Health / Clinical medicine / Clinical pharmacology / GABAA receptor positive allosteric modulators / Complement deficiency / Hereditary angioedema / Serpinopathies / Icatibant / Adverse effect / Clinical trial / Zolpidem

Microsoft Word - FIRAZYR.Product Monographdoc

DocID: 1qA9x - View Document

Medicine / CSL Behring / Clinical medicine / Microbiology / Coagulation system / CSL Limited / Hereditary angioedema / Behring / CSL / Coagulation / Marburg

Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop

DocID: 1pVHk - View Document